our leadership bg headline img

See the latest on what’s happening with
Luzsana Biotechnology

Press releases

Camrelizumab in Combination with Rivoceranib (Apatinib) Significantly Prolonged Overall Survival and Progression-Free Survival vs. Sorafenib in Patients with Unresectable Hepatocellular Carcinoma in a Multinational Phase 3 Trial, a Joint Program with Elevar Therapeutics

Read the press release >

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) launches Luzsana Biotechnology (Luzsana)

Read the press release >
our approach bg

Thank you for registering

Stay tuned for future communications from Luzsana Biotechnology™.